Company Overview of ContraVir Pharmaceuticals, Inc.
ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. Its lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is in Phase 3 clinical development. The FV-100 is also being developed for post-herpetic neuralgia that is in Phase 2 clinical study. The company is also developing CMX157, which is in Phase 2 clinical studies for the Hepatitis B virus. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.
399 Thornall Street
Edison, NJ 08837
Founded in 2013
Key Executives for ContraVir Pharmaceuticals, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $525.0K
Chief Medical Officer
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2015.
ContraVir Pharmaceuticals, Inc. Key Developments
ContraVir Pharmaceuticals, Inc. Presents at NobleCon12, the 12th Annual Emerging Growth Investor Conference, Jan-18-2016 12:00 PM
Jan 8 16
ContraVir Pharmaceuticals, Inc. Presents at NobleCon12, the 12th Annual Emerging Growth Investor Conference, Jan-18-2016 12:00 PM. Venue: Club Med Sandpiper Bay, Port St. Lucie, Florida, United States. Speakers: James E. Sapirstein, Chief Executive Officer and Director.
ContraVir Pharmaceuticals, Inc., Annual General Meeting, Feb 04, 2016
Dec 15 15
ContraVir Pharmaceuticals, Inc., Annual General Meeting, Feb 04, 2016, at 10:00 US Eastern Standard Time. Location: offices of the Company 399 Thornall Street, First Floor Edison 08837 New Jersey United States Agenda: To elect six (6) directors for a one-year term to expire at the 2016 annual meeting of stockholders; to ratify the appointment of BDO USA, LLP as independent registered public accounting firm for the fiscal year ending June 30, 2016; and to transact any other business that may properly come before annual meeting or any adjournment or postponement of the meeting.
ContraVir Pharmaceuticals, Inc. Reports Positive Results from CMX157
Dec 8 15
ContraVir Pharmaceuticals, Inc. reported positive results regarding CMX157's significantly enhanced potency against hepatitis B virus (HBV), now determined to be 97-fold compared to tenofovir (TFV), based on in vitro studies. These results from head-to-head studies support CMX157's potential for an enhanced safety profile compared to Gilead's tenofovir DF (Viread). ContraVir Pharmaceuticals, Inc. reported positive results regarding CMX157's significantly enhanced potency against hepatitis B virus (HBV), now determined to be 97-fold compared to tenofovir (TFV), based on in vitro studies. These results from head-to-head studies support CMX157's potential for an enhanced safety profile compared to Gilead's tenofovir DF (Viread). The data were presented at HEP DART 2015 by John Sullivan-Bolyai, MD, MPH, Chief Medical Officer of ContraVir, who stated, These compelling results, derived from in vitro studies, show that CMX157 potentially demonstrates equal, if not better, antiviral activity at low doses compared to Viread. Consistently shown that CMX157 not only has less cytotoxicity than Viread in vitro along with a low potential for mitochondrial toxicity, but should significantly reduce the amount of TFV exposure outside the liver, further enhancing the safety profile of CMX157 compared to Viread. These favorable results provide a solid foundation for advancing the company's Hepatitis B clinical program. Final results, from a greater number of experiments, improved upon earlier estimates of 60-fold greater potency of CMX157 compared to TFV. CMX157 demonstrates a potential enhanced safety profile compared to Viread (Tenofovir DF, TDF) - CMX157 exhibited a low potential for mitochondrial toxicity in a standard assay of mitochondrial integrity under glucose vs. galactose growth conditions, confirming previous in vitro results. CMX157 was less cytotoxic than TDF, based on IC50 concentrations that were consistently similar to or higher than TDF across a large panel of diverse cell lines. CMX157 is 97-fold more active against HBV than TFV in vitro. Final results, from a greater number of experiments, improved upon earlier estimates of 60-fold greater potency of CMX157 compared to TFV. The amount of drug required to inhibit HBV DNA in HepG2.2.15 liver cells was dramatically lower (EC50 = 15.03 +/- 4.31 nM) for CMX157 compared to TFV (EC50 1460 +/- 1127 nM). CMX157 is highly liver targeted (rat model), limiting exposure of other tissues to TFV. After a single, oral dose, 86% of absorbed CMX157 was rapidly extracted by the liver. Blood levels of CMX157 peaked at 1-3 hours and then declined rapidly, becoming undetectable after 6 hours; only low levels of TFV were detected in the peripheral circulation. There was no substantial accumulation or retention in the heart following oral or intravenous administration. CMX157 is rapidly and efficiently converted to the active antiviral, TFV diphosphate by liver cells, consistent with its improved antiviral activity and potential for dose reduction. CMX157 was efficiently metabolized by hepatocytes into active TFV diphosphate (TFV-PP). CMX157 metabolism in vitro was time- and dose-dependent, yielding proportional levels of TFV and TFV-PP over time, during which liver cells remained fully viable. CMX157 showed only minimal metabolism by cardiomyocytes in vitro compared to Viread. CMX157 exhibits low potential for drug-drug interactions. CMX157 did not exhibit significant induction/inhibition of key metabolic enzymes or transporters in vitro.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 26, 2015